Epicrispr Biotechnologies to Begin Clinical Trials for its Lead Epigenetic Therapy for FSHD Patients
The therapy, EPI-321, is intended to treat cases of facioscapulohumeral muscular dystrophy, a genetic neuromuscular disorder.
3hon MSN
U.S. cars; threatens E.U. and Canada with higher levies: Live - President insists move will boost American auto manufacturing ...
Yoga pants are my safe place. They’re soft, stretchy, breathable, and really easy to style (read: I don’t have to worry about ...
Nike on Thursday warned that sales will drop by a double digit percentage in its current quarter as the sneaker giant contends with new tariffs, sliding consumer confidence and a slower than expected ...
Lululemon Athletica Inc. delivered a gloomy outlook for the year ahead amid slow sales for the yogawear brand in the US.
Lululemon beat Wall Street expectations for fiscal fourth-quarter earnings and revenue, but issued 2025 guidance that ...
The activewear company said it expects sales of $11.15 billion to $11.3 billion for its fiscal 2025, the high-end of which is ...
Iowa’s Republican attorney general is suing a county sheriff over his Facebook post saying his department doesn’t always need ...
Beyond the usual tips and tricks, our mums have also passed down traditions that are foundational to our cultures, making us ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results